SEC Company Response from Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281) (ELDN) — Jun 14, 2019
Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281)
Date: June 14, 2019 · CIK: 0001404281 · Accession: 0001193125-19-173656
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232011
Letter
Novus Therapeutics, Inc.
19900 MacArthur Blvd., Suite 550
Irvine, CA 92612
(949) 238-8090
June 14, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Sonia Bednarowski
Re: Novus Therapeutics, Inc.
Registration Statement on Form S-1
Filed June 7, 2019
File No. 333-232011
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, Novus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company (the “Registration Statement”) be accelerated to 4:01 p.m., Eastern Daylight Time, on June 17, 2019 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Novus Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Novus Therapeutics, Inc. 19900 MacArthur Blvd., Suite 550 Irvine, CA 92612 (949) 238-8090 June 14, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Sonia Bednarowski Re: Novus Therapeutics, Inc. Registration Statement on Form S-1 Filed June 7, 2019 File No. 333-232011 Ladies and Gentlemen: Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, Novus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company (the “Registration Statement”) be accelerated to 4:01 p.m., Eastern Daylight Time, on June 17, 2019 or as soon thereafter as practicable. [Signature page follows] Very truly yours, Novus Therapeutics, Inc. By: /s/ Gregory J. Flesher Name: Gregory J. Flesher Title: Chief Executive Officer cc: Ryan A. Murr, Gibson, Dunn & Crutcher LLP